OverviewSuggest Edit

BioNTech is a biopharmaceutical company developing therapies against cancer and infectious diseases. It provides peptide manufacturing services, GMP (good manufacturing practice) manufacturing services for mRNA and cell and gene therapies, and research services. The company also develops and manufactures biomarker-based in vitro diagnostic devices (IVDD) and commercializes products through selected partners. BioNTech covers a range of platforms, including mRNA therapeutics, engineered cell therapies, antibodies, and small molecule immunomodulators.
TypePublic
Founded2008
HQMainz, DE
Websitebiontech.de
Employee Ratings3.6

Latest Updates

Employees (est.) (Dec 2019)1,300(+19%)
Revenue (FY, 2019)€2 M(-98%)
Share Price (Jan 2021)€88
Cybersecurity ratingBMore

Key People/Management at BioNTech

Sean Marett

Sean Marett

Chief Business and Chief Commercial Officer
Ugur Sahin

Ugur Sahin

Chief Executive Officer
Sierk Poetting

Sierk Poetting

Chief Financial Officer and Chief Operating Officer
Ryan Richardson

Ryan Richardson

Chief Strategy Officer
Ozlem Tureci

Ozlem Tureci

Chief Medical Officer
Richard Gaynor

Richard Gaynor

President of BioNTech US and Chief of R&D
Show more

BioNTech Office Locations

BioNTech has offices in Mainz, Halle (Saale), Idar-Oberstein, Marburg and in 4 other locations
Mainz, DE (HQ)
An der Goldgrube 12
Halle (Saale), DE
Weinbergweg 23
Idar-Oberstein, DE
Vollmersbachstraße 66
Marburg, DE
Emil-von-Behring-Straße 76
Neuried, DE
Forstenrieder Str. 8
Planegg, DE
Am Klopferspitz 19a
Show all (8)

BioNTech Financials and Metrics

BioNTech Revenue

Embed Graph
View revenue for all periods
BioNTech's revenue was reported to be €1.99 m in FY, 2019
EUR

Revenue (FY, 2019)

2.0m

Gross profit (FY, 2019)

(15.4m)

Gross profit margin (FY, 2019), %

(774.6%)

Net income (FY, 2019)

(179.2m)

EBIT (FY, 2019)

(181.5m)

Market capitalization (22-Jan-2021)

21.0b

Closing stock price (22-Jan-2021)

88.0

Cash (31-Dec-2019)

519.1m
BioNTech's current market capitalization is €21 b.
EURFY, 2017FY, 2018FY, 2019

Revenue

61.6m127.6m2.0m

Revenue growth, %

107%

Cost of goods sold

9.3m13.7m17.4m

Gross profit

52.3m113.9m(15.4m)
Annual
EURFY, 2017FY, 2018FY, 2019

Cash

172.1m411.5m519.1m

Accounts Receivable

4.6m18.9m11.9m

Inventories

11.7m

Current Assets

172.1m449.0m560.2m
Quarterly
EURQ2, 2019

Cash

284.9m

Accounts Receivable

8.9m

Current Assets

504.3m

PP&E

123.1m
Annual
EURFY, 2017FY, 2018FY, 2019

Net Income

(85.9m)(48.3m)(179.2m)

Depreciation and Amortization

10.5m22.0m33.9m

Inventories

(574.0k)(1.3m)

Cash From Operating Activities

(4.6m)(58.2m)(198.5m)
Quarterly
EURQ2, 2018Q2, 2019

Net Income

(23.3m)(90.8m)

Depreciation and Amortization

8.8m15.6m

Inventories

(902.0k)(1.4m)

Cash From Operating Activities

(69.7m)(85.7m)
EURFY, 2017

Debt/Equity

-1.1 x

Debt/Assets

0.1 x

Financial Leverage

-7.8 x
Show all financial metrics

BioNTech Operating Metrics

Oct, 2019

Patents (US)

45

Phase I Trials Products

8

Phase II Trials Products

1

Pre-Clinical Phase Products

11
Show all operating metrics

BioNTech Acquisitions / Subsidiaries

Company NameDateDeal Size
Apta IT
BioNTech Austria Beteiligungen GmbH
BioNTech Business Services
BioNTech Cell & Gene Therapies
BioNTech Diagnostics
BioNTech Innovative Manufacturing Services
BioNTech Protein Therapeutics
BioNTech Real Estate GmbH & Co. KG
BioNTech Real Estate Verwaltungs
BioNTech Research and Development
Show more

BioNTech Revenue Breakdown

Embed Graph

BioNTech revenue breakdown by business segment: 20.2% from Other Sales Transactions and 79.8% from Collaboration Revenue

BioNTech Cybersecurity Score

Cybersecurity ratingPremium dataset

B

85/100

SecurityScorecard logo

BioNTech Online and Social Media Presence

Embed Graph

BioNTech News and Updates

BioNTech, Pfizer to sell 40 million doses to lower-income countries

BioNTech SE and Pfizer Inc. said Friday that they plan to sell 40 million doses of their COVID-19 vaccine this year to Covax, a group that aims to ensure 92 lower-income countries have access to coronavirus vaccines. BioNTech's stock gained 1.2% in trading on Friday, while shares of Pfizer were up…

Pfizer and BioNTech Reach Agreement with COVAX for Advance Purchase of Vaccine to Help Combat COVID-19

NEW YORK CITY, NY and MAINZ, GERMANY, January 22, 2021 (GLOBE NEWSWIRE) — Pfizer and BioNTech SE today announced an advance purchase agreement with COVAX for up to 40 million doses of the Pfizer-BioNTech COVID-19 Vaccine. The doses will be delivered throughout 2021.

Pfizer and BioNTech will reportedly supply COVID-19 shots to COVAX, the WHO's vaccine scheme for poorer countries, following Biden's commitment to the program

Summary List PlacementPfizer and BioNTech will supply COVID-19 vaccines to COVAX, the World Health Organization (WHO) scheme designed to share doses with poorer countries, two sources with knowledge of the matter told Reuters. The number of doses Pfizer and BioNTech share with the scheme would lik…

Pfizer and BioNTech Publish Results of Study Showing COVID-19 Vaccine Elicits Antibodies that Neutralize Pseudovirus Bearing the SARS-CoV-2 U.K. Strain Spike Protein in Cell Culture

New York and Mainz, Germany, January 20, 2021 — Today, Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced results from an in vitro study that provides additional data on the capability of sera from individuals immunized with the Pfizer-BioNTech COVID-19 vaccine BNT162b2 to neutralize t…

Pfizer, BioNTech Shot Likely to Defeat Mutant, New Study Shows

Pfizer, BioNTech Shot Likely to Defeat Mutant, New Study Shows

BioNTech Billionaires Back Startup Trying to Keep Trains on Time

BioNTech Billionaires Back Startup Trying to Keep Trains on Time
Show more

BioNTech Blogs

Overview COVID-19

Overview COVID-19 admin Wed, 12/02/2020 - 00:45

HCP 3 Role of Vaccines in Pandemic

HCP 3 Role of Vaccines in Pandemic admin Sun, 11/29/2020 - 20:09

HCP 2 The Disease COVID-19

HCP 2 The Disease COVID-19 admin Sun, 11/29/2020 - 20:09

HCP 5 Biontechs Sars-Cov-2 Vaccine Candidates

HCP 5 Biontechs Sars-Cov-2 Vaccine Candidates admin Sun, 11/29/2020 - 20:09

HCP 4 Technology Platforms for COVID-19 vaccines

HCP 4 Technology Platforms for COVID-19 vaccines admin Sun, 11/29/2020 - 20:09

HCP 1 The Virus Sars Cov 2

HCP 1 The Virus Sars Cov 2 admin Sun, 11/29/2020 - 20:09
Show more

BioNTech Frequently Asked Questions

  • When was BioNTech founded?

    BioNTech was founded in 2008.

  • Who are BioNTech key executives?

    BioNTech's key executives are Sean Marett, Ugur Sahin and Sierk Poetting.

  • How many employees does BioNTech have?

    BioNTech has 1,300 employees.

  • What is BioNTech revenue?

    Latest BioNTech annual revenue is €2 m.

  • What is BioNTech revenue per employee?

    Latest BioNTech revenue per employee is €1.5 k.

  • Who are BioNTech competitors?

    Competitors of BioNTech include Kite Pharma, 3sbio and Evotec.

  • Where is BioNTech headquarters?

    BioNTech headquarters is located at An der Goldgrube 12, Mainz.

  • Where are BioNTech offices?

    BioNTech has offices in Mainz, Halle (Saale), Idar-Oberstein, Marburg and in 4 other locations.

  • How many offices does BioNTech have?

    BioNTech has 8 offices.